Mergers and Acquisitions - ShenKai Co., Ltd. plans to acquire 51% equity of Blue Ocean Zhixin for a transaction price of 60 million yuan, aiming to enhance drilling efficiency and risk management in the oil and gas industry [1] - YingLiu Co., Ltd. intends to acquire minority shares of its subsidiary YingLiu Aviation for a base price of 484 million yuan, which will increase its ownership to 90% [3] - YueHongYuan A has terminated its major asset restructuring plan due to failure to reach an agreement on core terms with the counterparty [2] Shareholding Changes - Nanwei Software's controlling shareholder plans to reduce its stake by up to 2%, equating to a maximum of 11.6072 million shares [4] - Aladdin's employee stock ownership platform intends to sell up to 2.4 million shares, representing no more than 0.7216% of the total share capital [5] - Guangdong Mingzhu's shareholder plans to reduce its stake by up to 1.5%, which amounts to a maximum of 10.4161 million shares [6] Risk Matters - Zhang Xiaoqin's controlling shareholder has entered a restructuring process as the court has accepted its application for reorganization [7] - *ST Jinguang has received a decision to terminate its stock listing, with the last trading date expected to be July 18, 2025 [8] - Zhongguancun has reported that part of its bank account funds, totaling 2.352 million yuan, have been frozen, which is a small percentage of its audited monetary funds and net assets [9]

Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by Shanghai Aladdin Biochemical Technology Co., Ltd.'s employee shareholding platform, Shanghai Jingzhen Cultural and Artistic Development Center (Limited Partnership), which intends to reduce its holdings in the company through a centralized bidding method within a specified timeframe [1][2]. Group 1: Shareholder Information - As of the announcement date, the employee shareholding platform holds 9,781,190 shares, accounting for 2.94% of the company's total share capital [1][2]. - The shares held by the platform were acquired prior to the company's initial public offering (IPO) and through capital reserve conversion [1][2]. Group 2: Reduction Plan Details - The reduction plan allows for a maximum of 2,400,000 shares to be sold, representing up to 0.7216% of the total share capital [4][8]. - The reduction period is set from July 14, 2025, to October 13, 2025, starting 15 trading days after the disclosure of the reduction plan [1][4]. Group 3: Conditions and Adjustments - The selling price will be determined based on market conditions, and any corporate actions such as dividends or stock splits during the reduction period will lead to adjustments in the reduction plan [2][8]. - The shareholder has committed to not reducing shares in the six months following the announcement, aligning with previous commitments made [7][8]. Group 4: Compliance and Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's guidelines [8]. - The company assures that the reduction will not affect its governance or ongoing operations [8].

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-047 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于公司股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 截至本公告披露之日，上海阿拉丁生化科技股份有限公司（以下简称"公司"） 的员工持股平台上海晶真文化艺术发展中心（有限合伙）（以下简称"晶真文化"） 持有公司股份 9,781,190 股，占公司总股本 2.94%，上述股份来源为公司首次公 开发行前取得的股份及通过公司实施权益分派资本公积金转增股本取得的股份， 上述股份已上市流通。股东晶真文化的执行事务合伙人为公司控股股东、实际控 制人招立萍女士。 减持计划的主要内容 公司员工持股平台晶真文化持有的股份为首次公开发行前公司实施的员工 股权激励，晶真文化拟通过集中竞价方式减持其所持有的公司股份合计不超过 2,400,000 股（含本数），拟 ...

阿拉丁公告，股东晶真文化拟通过集中竞价方式减持不超过240万股，占公司总股本的0.7216%。减持 计划将于2025年7月14日至2025年10月13日期间进行，减持价格按市场价格确定。晶真文化目前持股 978.12万股，占公司总股本2.94%。 ...

Core Viewpoint - The company, Shanghai Aladdin Biochemical Technology Co., Ltd., is set to hold an investor briefing on June 30, 2025, to discuss its 2024 annual report and Q1 2025 results, allowing investors to engage and ask questions [2][3][4]. Group 1: Meeting Details - The investor briefing will take place on June 30, 2025, from 09:00 to 10:00 [5]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [5]. - The meeting will be conducted in an interactive online format, enabling real-time communication with investors [3][5]. Group 2: Participation Information - Investors can submit questions from June 23 to June 27, 2025, via the Roadshow Center website or through the company's email [2][4]. - The company will address commonly asked questions during the briefing [3][4]. - Key personnel participating in the meeting include the Chairman and General Manager, Xu Jiuzhen, and the Secretary of the Board, Zhao Xin'an [4]. Group 3: Contact Information - For inquiries, investors can contact the Securities Affairs Department at 021-50560989 or via email at aladdindmb@163.com [6]. - After the briefing, the main content and outcomes will be available on the Roadshow Center website [6].

| | | 上海阿拉丁生化科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 06 月 30 日 （星期一） 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 06 月 23 日（星期一）至 06 月 27 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 aladdindmb@163.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海阿拉丁生化科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日发布公司 2024 年度报告及 2025 年第一季度报告，为便于广大投资者更全 面深入地了解公司 2024 年度及 2025 年第一季度经 ...

Investment Rating - The report maintains a "Recommended" rating for the new materials industry [1][17]. Core Viewpoints - The new materials sector is a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to enter a phase of accelerated long-term growth. The report emphasizes that "one generation of materials supports one generation of industry," highlighting the foundational nature of the new materials industry as the material basis for other industries [4][17]. Summary by Sections 1. New Materials Industry Dynamics 1.1 Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials [5]. - The global first AI-based processor chip design system "Enlightenment" was recently launched, achieving full automation in chip design, with significant performance metrics surpassing human-designed levels [6][24]. 1.2 Aerospace Sector - Key areas of interest include PI films, precision ceramics, and carbon fibers [7]. 1.3 New Energy Sector - Focus on photovoltaic materials, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [9]. - The International Energy Agency (IEA) predicts a 70% increase in global investment in clean hydrogen compared to 2024, with total spending expected to reach approximately $7.8 billion in 2025 [10]. 1.4 Biotechnology Sector - Key areas include synthetic biology and scientific services [11]. 1.5 Energy Conservation and Environmental Protection Sector - Focus on adsorbent resins, membrane materials, and biodegradable plastics [13]. 2. Key Companies and Profit Forecasts - The report lists several key companies with their respective stock prices and earnings per share (EPS) forecasts for 2024 to 2026, indicating a positive outlook for many companies in the new materials sector [16].

Group 1 - The stock price of Aladdin (688179) closed at 12.04 yuan on June 13, 2025, down 1.15% from the previous week [1] - The highest intraday price for Aladdin on June 9 was 12.68 yuan, while the lowest on June 13 was 12.01 yuan [1] - Aladdin's current total market capitalization is 4.005 billion yuan, ranking 98th out of 169 in the chemical products sector and 3526th out of 5150 in the A-share market [1] Group 2 - Changes in tariff policies are driving the ongoing process of domestic substitution, with Aladdin's products having over 230,000 citations in SCI papers, indicating increasing brand recognition [2][3] - The company is considering mergers and acquisitions as a means to achieve external growth, with a favorable policy environment for such activities [2][3] - Future sales strategies will focus on an e-commerce model, maintaining a balance between direct sales to large clients and encouraging small clients to order through e-commerce platforms, with distributors covering part of the channel [2][3]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report emphasizes that the ASCO conference has catalyzed enthusiasm for innovative drug investments, with a notable increase in the number of presentations by Chinese experts [3][12] - It is believed that innovative drugs will remain the main focus of pharmaceutical investments in the medium to long term, driven by China's transition from quantity to quality and innovation in drug development, alongside increasing policy support [3][12] - Short-term factors such as US-China tariff disputes and geopolitical tensions may affect overall risk appetite, suggesting a focus on companies that can commercialize large-scale innovative drugs and those in the CXO and life sciences upstream sectors [3][12] Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's weekly return was 2.21%, outperforming the CSI 300 by 3.30%, ranking second among 31 primary sub-industry indices [10] - The chemical pharmaceuticals sub-sector led with a weekly return of 3.83% [10][27] - Over the past month, the sector's return was 6.42%, again ranking second among sub-industry indices [10][17] Industry Dynamics - The report highlights the importance of the ASCO conference held from May 30 to June 3, 2025, in Chicago, which has further stimulated investment interest in innovative drugs [11][12] - The report suggests focusing on the CXO and life sciences upstream sectors, as well as traditional pharmaceutical companies transitioning from generics to innovative drugs [13][14] Recommendations - Companies to watch in the innovative drug chain include Tigermed, WuXi AppTec, and others in the CRO/CDMO space [13] - For the domestic recovery line, companies like Aier Eye Hospital and Tongrentang are recommended [13] - In the self-sufficiency line, high-end medical devices and research instruments from companies like Mindray and Hualan Biological Engineering are highlighted [14] Company-Specific Insights - The report identifies specific companies with strong growth potential, such as Yaoshi Bang, which is expected to achieve a CAGR of approximately 145% in net profit from 2024 to 2027 [15] - Kangchen Pharmaceutical has maintained a net profit growth rate of over 14% for the past three years, with a projected PE of about 8 times in 2025 [15] - Guoyuyuan is expected to see operational improvements in 2025, marking a potential turning point for the company [15][16]

Group 1 - The core viewpoint of the news is that Aladdin, a listed company, is experiencing significant growth in its research reagent business, with a wide range of industries as clients, including life sciences, aerospace, new materials, new energy, pharmaceuticals, food, chemicals, and third-party testing [1] - Aladdin's products have been cited in over 230,000 SCI papers, indicating a strong recognition of the brand and a remarkable annual growth in literature citations [1] - The future sales strategy for Aladdin includes a combination of e-commerce for small customers and direct sales for large clients, with distributors also playing a role in channel coverage [1] Group 2 - Zhejiang Yongxi Investment Management Co., Ltd. was established in November 2015 with a registered capital of 30 million RMB and has been recognized as a private investment fund manager [2] - The company focuses on providing professional asset and wealth management services, with a team that has over 20 years of experience in the securities and futures market [2] - Currently, Yongxi Investment manages approximately 500 million RMB in assets across six funds, including two securities investment funds and four equity investment funds [2]